The RELAZA2 long-term follow-up, published in Blood, extends earlier pilot work from Dresden (2005-2011) into a multicenter prospective study within the Study Alliance Leukemia network. While not an RCT, this single-arm design with MRD-triggered azacitidine intervention in AML/MDS post-transplant or post-chemotherapy patients demonstrates that molecular detection of impending relapse can trigger preemptive treatment before overt disease, yielding meaningful delay in progression. Sample size and exact hazard ratios are not detailed in initial coverage, yet the absence of randomization limits causal claims and raises risks of selection bias. This builds on the 2018 RELAZA2 interim report and aligns with broader evidence from observational cohorts, such as a 2022 meta-analysis in Lancet Haematology (n>2,000 AML patients) confirming MRD negativity as a surrogate for survival. The original MedicalXpress piece underplays conflicts of interest around Dresden's NCT/UCC leadership and omits how RELAZA2's approach prefigures ctDNA-guided trials now underway in solid tumors. Overall, these data accelerate the move from static risk stratification to dynamic, response-adapted care with direct survival implications.